11/4/2025

Janusmed sex and gender

Janusmed sex and gender – Regorafenib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Regorafenib

Regorafenib

Class : C

Show all info

Print

Contact us

  1. Yang Y, Wang G, He J, Ren S, Wu F, Zhang J et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer. 2017;141(10):1942-1949.

  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.

  3. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.

  4. Ren X, Wang G, Chen J, Liu L. A population-based analysis of gender differences in survival outcomes for gastric gastrointestinal stromal tumors. J Gastrointest Surg. 2025;29(6):102055.

  5. Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9(12):104002.

  6. Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol. 2020;86(12):2362-2376.

  7. Barzi A. Review of third-line treatment strategies in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2024;22 Suppl 4(5):3-10.

  8. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.

  9. Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20(4):326-333.

  10. Stivarga (regorafenib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-07, cited 2025-10-03]

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Yang Y, Wang G, He J, Ren S, Wu F, Zhang J et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer. 2017;141(10):1942-1949.
  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.
  3. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.
  4. Ren X, Wang G, Chen J, Liu L. A population-based analysis of gender differences in survival outcomes for gastric gastrointestinal stromal tumors. J Gastrointest Surg. 2025;29(6):102055.
  5. Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9(12):104002.
  6. Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol. 2020;86(12):2362-2376.
  7. Barzi A. Review of third-line treatment strategies in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2024;22 Suppl 4(5):3-10.
  8. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.
  9. Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20(4):326-333.
  10. Stivarga (regorafenib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-07, cited 2025-10-03]
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]